Nivolumab shows signs of superior response rate compared to standard chemo in advanced melanoma
The monoclonal antibody nivolumab achieves superior response rates and a longer duration of response than standard chemotherapy[1] in patients whose melanoma has progressed after treatment with ipilimumab, according to phase ...
Sep 29, 2014
0
0